1434 related articles for article (PubMed ID: 11691802)
1. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi N; Haba A; Matsuno F; Seon BK
Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
[TBL] [Abstract][Full Text] [Related]
2. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
[TBL] [Abstract][Full Text] [Related]
3. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies.
Matsuno F; Haruta Y; Kondo M; Tsai H; Barcos M; Seon BK
Clin Cancer Res; 1999 Feb; 5(2):371-82. PubMed ID: 10037187
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies.
Tabata M; Kondo M; Haruta Y; Seon BK
Int J Cancer; 1999 Aug; 82(5):737-42. PubMed ID: 10417773
[TBL] [Abstract][Full Text] [Related]
5. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites.
Tsujie M; Uneda S; Tsai H; Seon BK
Int J Oncol; 2006 Nov; 29(5):1087-94. PubMed ID: 17016638
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis and metastasis marker of human tumors.
Seon BK; Takahashi N; Haba A; Matsuno F; Haruta Y; She XW; Harada N; Tsai H
Rinsho Byori; 2001 Oct; 49(10):1005-13. PubMed ID: 11769465
[TBL] [Abstract][Full Text] [Related]
7. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells.
She X; Matsuno F; Harada N; Tsai H; Seon BK
Int J Cancer; 2004 Jan; 108(2):251-7. PubMed ID: 14639611
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.
Tsujie M; Tsujie T; Toi H; Uneda S; Shiozaki K; Tsai H; Seon BK
Int J Cancer; 2008 May; 122(10):2266-73. PubMed ID: 18224682
[TBL] [Abstract][Full Text] [Related]
9. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin.
Takahashi N; Kawanishi-Tabata R; Haba A; Tabata M; Haruta Y; Tsai H; Seon BK
Clin Cancer Res; 2001 Mar; 7(3):524-32. PubMed ID: 11297243
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1998; 18(3A):1485-500. PubMed ID: 9673360
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin.
Shiozaki K; Harada N; Greco WR; Haba A; Uneda S; Tsai H; Seon BK
Cancer Immunol Immunother; 2006 Feb; 55(2):140-50. PubMed ID: 15856228
[TBL] [Abstract][Full Text] [Related]
12. Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature.
Uneda S; Toi H; Tsujie T; Tsujie M; Harada N; Tsai H; Seon BK
Int J Cancer; 2009 Sep; 125(6):1446-53. PubMed ID: 19533687
[TBL] [Abstract][Full Text] [Related]
13. Endoglin-targeted cancer therapy.
Seon BK; Haba A; Matsuno F; Takahashi N; Tsujie M; She X; Harada N; Uneda S; Tsujie T; Toi H; Tsai H; Haruta Y
Curr Drug Deliv; 2011 Jan; 8(1):135-43. PubMed ID: 21034418
[TBL] [Abstract][Full Text] [Related]
14. Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neo-vascularization.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1998; 18(5A):3621-8. PubMed ID: 9858949
[TBL] [Abstract][Full Text] [Related]
15. Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.
Pernasetti F; Nickel J; Clark D; Baeuerle PA; Van Epps D; Freimark B
Int J Oncol; 2006 Dec; 29(6):1371-9. PubMed ID: 17088974
[TBL] [Abstract][Full Text] [Related]
16. Facilitation of endoglin-targeting cancer therapy by development/utilization of a novel genetically engineered mouse model expressing humanized endoglin (CD105).
Toi H; Tsujie M; Haruta Y; Fujita K; Duzen J; Seon BK
Int J Cancer; 2015 Jan; 136(2):452-61. PubMed ID: 24866768
[TBL] [Abstract][Full Text] [Related]
17. Immunocytochemical detection of endoglin is indicative of angiogenesis in malignant melanoma.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1998; 18(4A):2701-10. PubMed ID: 9703932
[TBL] [Abstract][Full Text] [Related]
18. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ
Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651
[TBL] [Abstract][Full Text] [Related]
19. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis.
Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE
Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822
[TBL] [Abstract][Full Text] [Related]
20. CD105 is important for angiogenesis: evidence and potential applications.
Duff SE; Li C; Garland JM; Kumar S
FASEB J; 2003 Jun; 17(9):984-92. PubMed ID: 12773481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
